Social Disparities in Cancer Survival: Methodological Considerations

Belot, Aurélien; Perme, Maja Pohar

doi:10.1007/978-3-030-69329-9_5

Cited by 2 publications

(3 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondly, the other‐cause mortality hazard of the general population is equal to the other‐cause mortality hazard in the population analysed, within levels defined by the demographic characteristics available in the lifetable. More details on the conditions and applicability of such approaches can be found in dedicated papers 7,16–18 …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Long‐term excess mortality and net survival among elderly diffuse large B‐cell lymphoma patients after front‐line R‐CHOP treatment

et al. 2023

Self Cite

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma, as it represents 30%-40% of all non-Hodgkin lymphoma cases. Patients diagnosed with DLBCL may be cured in up to 50%-60% of the patients who achieve a complete remission after front-line treatment. However elderly patients may display a worse prognosis, 1 even in the era of chemo-immunotherapy, 2,3 with elderly males having the worst overall survival (OS) of all patient subgroups. Data on the prognosis of DLBCL patients in the longer run and especially among an elderly population after front-line R-CHOP (rituximab associated with doxorubicin, cyclophosphamide, vincristine and prednisone) are scarce, even taking into account that approximately half of the patients with DLBCL are older than 60 years old. A prospective long-term follow-up programme on data of the LNH03-6B trial, 4 in which 60to 80-year-old patients were randomized, was implemented to collect vital status among patients alive at the end of the trial. In this recent report, the 10-year progression-free survival (PFS) and overall survival (OS) were 40.4% and 49.8% respectively, slightly higher than those in the R-CHOP arm of the LNH-98.5 trial (10-year PFS and OS: 36.5% and 43.5% respectively), which involved a similar population. 5 Nevertheless, considering the treatment outcomes for this population of patients with a number of competing risks for death and only 3.7% of relapses beyond five years after front-line treatment, it is important to investigate long-term DLBCL-specific mortality hazard as compared with the expected mortality hazard in the general population. Indeed,

show abstract

Section: Methodsmentioning

confidence: 99%

“…More details on the conditions and applicability of such approaches can be found in dedicated papers. 7,[16][17][18]…”

Section: Relative Survival Approachesmentioning

confidence: 99%

Long‐term excess mortality and net survival among elderly diffuse large B‐cell lymphoma patients after front‐line R‐CHOP treatment

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Finally, the authors proposed prioritising cancer control across Europe. An EU-wide study realised by Belot & Pohar-Perme [23] highlighted the disparities that existed between European citizens in relation to the widening gap between health progress and health equity. In the field of cancer, the authors stated that there are 200 diseases, which requires a systems approach to understanding cancer.…”

Section: Literature Reviewmentioning

confidence: 99%

New Regional Dynamic Cancer Model across the European Union

Negoiță

Ionescu

Zlati

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: Can increasing levels of economic wealth significantly influence changes in cancer incidence and mortality rates? Methods: We investigated this issue by means of regression analyses based on the study of incidence and mortality indicators for lip, oral cavity, and pharyngeal; colon; pancreatic; lung; leukaemia; brain and central nervous system cancers in correlation with the levels of economic welfare and financial allocations to health at the level of the European Union member states, with the exception of Luxembourg and Cyprus for which there are no official statistical data reported. Results: The results of the study showed that there were significant disparities both regionally and by gender, requiring corrective public policy measures that were formulated in this study. Conclusions: The conclusions highlight the main findings of the study in terms of the evolution of the disease, present the significant aspects that characterise the evolution of each type of cancer during the period analysed (1993–2021), and highlight the novelty and limitations of the study and future directions of research. As a result, increasing economic welfare is a potential factor in halting the effects of cancer incidence and mortality at the population level, while the financial allocations to health of EU member countries’ budgets are a drawback due to large regional disparities.

show abstract

Social Disparities in Cancer Survival: Methodological Considerations

Cited by 2 publications

References 65 publications

Long‐term excess mortality and net survival among elderly diffuse large B‐cell lymphoma patients after front‐line R‐CHOP treatment

Long‐term excess mortality and net survival among elderly diffuse large B‐cell lymphoma patients after front‐line R‐CHOP treatment

New Regional Dynamic Cancer Model across the European Union

Contact Info

Product

Resources

About